Akili initiated with an Equal Weight at Morgan Stanley

Morgan Stanley analyst Vikram Purohit initiated coverage of Akili with an Equal Weight rating and $2 price target. Akili is "a leading player" in the field of digital therapeutics, which aim to leverage software and algorithms to deliver therapeutic interventions to help treat or manage disease, Purohit tells investors. While he argues that Akili "presents intriguing science and promising clinical data," particularly in ADHD, Purohit sees uncertainties posed by the EndeavorRx launch and the potential for shares to be range-bound "until the launch can surpass investor expectations."